SGLT2 Inhibitor Cancer Risk Meta-Analysis: 28 Trials and 98,297 Participants

Jing Teng's systematic review and meta-analysis assesses the long-term safety of Sodium-glucose cotransporter 2 (SGLT2) inhibitors regarding cancer risk in patients with Type 2 diabetes, heart failure, and chronic kidney disease. The analysis includes 28 randomized controlled trials with 98,297 participants, published up to April 16, 2024. The dataset is a DOCX document containing the full meta-analysis results, registered in PROSPERO (CRD42024560310).

Use Cases

• Validate the safety profile of SGLT2 inhibitors for cancer risk based on pooled risk ratios from 28 trials.
• Compare cancer risk associations across different patient subgroups (e.g., HF, CKD) mentioned in the results.
• Inform clinical guidelines or drug safety reviews using the specific risk estimates for overall and common cancer types.

Strengths

• Analysis is based on 98,297 participants from 28 randomized controlled trials, providing a substantial evidence base.
• Includes specific pooled risk ratios (RR) with 95% confidence intervals for overall cancer risk and subgroup analyses.
• Registered in PROSPERO (CRD42024560310), indicating a predefined protocol.

Limitations

• The dataset is a 74.4 KB DOCX document; the underlying tabular data (e.g., study-level data) is not directly accessible in a structured format.
• Column-level documentation is absent; field semantics must be inferred from the document text after download.
• Row count for any underlying data tables is unknown, which may limit suitability assessment for computational analysis.

Provenance

Source

Jing Teng via figshare.

Collection Method

Systematic review and meta-analysis of studies from PubMed, CENTRAL, Web of Science, and ClinicalTrials.gov.

Time Range

Studies published up to April 16, 2024.

Freshness

Last updated 2026-05-08 05:57:10; freshness should be verified.